Sign In to Follow Application
View All Documents & Correspondence

Processes For Preparing (3 Sulfonamide 4 Chloro) Pyridine, (3 Sulfonamide 4 Fluoro) Pyridine Or (3 Sulfonamide 4 Bromo) Pyridine

Abstract: "PROCESSES FOR PREPARING (3-SULFONAMIDE-4-CHLORO) PYRIDINE, (3-SULFONAMIDE-4-FLUORO) PYRIDINE OR (3-SULFONAMIDE-4-BROMO) PYRIDINE"

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
23 September 2002
Publication Number
0
Publication Type
INA
Invention Field
GENERAL ENGINEERING
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2006-10-26
Renewal Date

Applicants

TEVA PHARMACEUTICAL INDUSTRIES, LTD.
5 BASEL STREET, P.O. BOX 3190, PETAH TIQVA 49131, ISRAEL.

Inventors

1. MARCO KORDOVA
78/14 ROTHCHILD, KFAR SABA, ISRAEL.

Specification

FORM 2
THE PATENTS ACT 1970
[39 OF 1970]
&
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION
[See Section 10; rule 13]
"PROCESSES FOR PREPARING (3-SULFONAMIDE-4-CHLORO)PYRIDINE,
(3-SULFONAMIDE-4-FLUORO)PYRIDINE OR (3-SULFONAMIDE-4-
BROMO)PYRIDINE"
TEVA PHARMACEUTICAL INDUSTRIES, LTD., of 5 Basel Street, P.O. Box 3190, Petah Tiqva 49131, Israel,
The following specification particularly describes the invention and the manner in which it is to be performed:
GRANTED 5-1-2006

ORIGINAL

The present invention relates to pricessis for preparing (3-sulfonamide-4-chloro)pyridine, ,3-sulfonannde-4-fluoro)pyridine or (3-sulfonamide-4-bromo)pyridine.
BACKGROUND OF THE INVENTION
l-Isopropyl-3-[(4-m-toluidino-3-pyridyl) sulfonyl] urea, which has the chemical structure

is approved, under the trademark DEMADEX®, by the U.S. Food and Drug Administration for the treatment of hypertension and edema associated with congestive heart failure, renal disease, or hepatic disease. The US AN approved generic name for this compound is torsemide, although this compound is also referred to as "torasemide" in the art. Torsemide is a loop diuretic that has been found to be particularly effective for the treatment of edema associated with chronic renal failure.
The synthesis of torsemide, torsemide intermediates and torsemide derivatives are described in the following references: Delarge, Ann. Pharm. Fr.3\, 467- 474 (1973); Delarge, Mem. Acad. R. Med. Belg. 47(3), 131-210 (1974); E. Koenigs et al, Chem. Ber. 57, 2080-2082 (1924); L. Thunus, Ann. Pharm. Fr. 33,487 - 494 (1975); Kondo, et al. Iyakuhin Kenkyu, 25(9), 734-50 (1994); EP 618,209; and U.S. Patent Nos. 2,516,025; 6,674,794; 4,244,950 and Re. 30,633; all of which are incorporated herein by reference.

4,244,950 and Re. 30,633; all of which are incorporated herein by reference.
A process for the preparation of the torsemide intermediates (3-sulfonamide-4-chloro)pyridine, 3-sulfomamide-4-(3'-methylphenyI) arninopyridine and torsemide is described in Scheme 1.
Scheme 1

In known processes where (3-sulfonarhide-4-chloro)pyridine is made from (3-sufonamide-4-chloro)pyridine (SCCPY -» SAMCPY), the reaction is performed in a polar solvent, such as, acetone or dioxane, or in melted reagent as a solvent in the presence of large excess of ammonium hydroxide. By these known processes, (3-sulfonylchloride-4-chloro)pyridine (SCCPY), isi added dropwise into an aqueous solution of ammonium hydroxide. The dropwise addition of (3-sulfonylchloride-4-chloro)pyridine into an excess of ammonium hydroxide is a method to try to minimize the condensation of (3-sulfonylchloride-4-chloro)pyridine with the newly formed desired product, (3-sulfonamide-4-chloro)pyridine (SAMPCY). These harsh reaction conditions necessitate a great effort in purifying the resulting product as
well as creating environmental waste disposal issues associated with


neutralizing and disposing of large volumes of concentrated basic solutions. The highly basic conditions make the procidurei employing a large excess of base very costly. Thus, in such conditions the desired (3-sulfonamide-4-chloro)pyridine is made in low yields, of about 50%, and is isolated with a high percentage of impurities thus requiring additional purification steps. It is desirable to have a process for making (3-sulfonamide-4-chlorolpyridine without the condensation of (3-sulfonylchloride-4-chloro)pyridine and (3-sulfonamide-4-chloro)pyridine. It is also desirable to have a process for making (3-sulfonamide-4-chloro)pyridine which gives high yields and high purity which is suitable for large scale manufacturing procedures.
In known processes where torsemide is made from S-sulfonamide-4-(3'-methylphenyl) aminopyridine, the reaction may be performed in dioxane or.dichloromethane in the presence of triethyl amine and isopropyl-isocyanate. Under such conditions the desired torsemide is made in low yields and is isolated with a high percentage of impurities thus requiring additional purification steps. The yields of these processes are low, highly variable and not are not suitable for large scale manufacturing processes. It is therefore desirable to have processes for making torsemide which gives high yields and high purity which uses solvents that are suitable for large scale manufacturing procedures.
SUMMARY OF THE INVENTION
The present invention relates to s process for making a compound of the formula:

comprising the steps of: (a) adding a compound of me formula
to an organic solvent; (b) adding ammonium hydroxide in an amount of about 1.75 to about 2.25 mole equivalents; and (c) isolating the compound of the formula:

WO 01/70226 PCT/US01/08866
, wherein X1 and X2 are each independently chloro, fiuoro or bromo.
In a preferred embodiment of the present invention, X1 and X2 are both chloro.
In another preferred embodiment of the present invention, the organic solvent is selected from the group consisting of t-butyl-methyl ether, toluene, acetonitrile, methyl-isobutyl ketone, ethyl-methyl ketone, acetone, benzene] xylene, ethanol and isopropanol.
In another embodiment of the present intention, the organic solvent is t-butyl-methyl ether.
In another embodiment of the present intention, the ammonia is an aqueous solution.
In another embodiment of the present intention, the ammonia is added to the solution of step (a).
In another embodiment of the present invention the ammonia is added in an amount of about 1.75 to about 2.25 mole equivalents
The present invention also relates to a process for making (3-sulfonamide-4-chloro)-pyridine comprising the steps of: (a) adding (3-sulfonylchloride-4-chloro)pyridine to an organic solvent; (b) adding ammonia; and isolating (3-suIfonamide-4-chloro)pyridine.
In a preferred embodiment of the present invention, the organic solvent is selected from the group consisting of t-butyl-methyl ether, toluene, acetonitrile, methyl isobutyl ketone, ethyl methyl ketone, acetone, benzene, xylene, ethanol and isopropanol. In another embodiment of the present intention, the organic solvent is t-butyl methyl ether. In another embodiment of the present intention, the ammonia is added as an aqueous solution. In another embodiment of the present intention, the ammonia is added to the solution of step (a). In another embodiment of the present invention, the ammonia is added in an amount of about 1.75 to about 2.25 mole equivalents
The present invention also relates to a process for preparing torsemide comprising the step of reacting 3-sulfonylamide-4(3 '-methylphenyl)-aminopyridine with isopropyl isocyanate in the presence of triethyl amine in a solvent selected from the group consisting of acetonitrile, toluene, acetone, ethyl acetate and butyl acetate, and mixtures thereof. In a preferred embodiment of the present invention, the solvent is acetone. In another preferred embodiment of the present invention, the solvent is acetonitrile.

WO 01/70226 PCT/US01/08866
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to new processes for making the torsemide intermediate
(3-sulfonamide-4-chloro)pyridine. The methods of the present invention provide for the
synthesis of (3-sulfonamide-4-chloro)pyridine in substantially higher yields and higher purity
than previously reported. The intermediate (3-sulfonylchloride-4-chloro)pyridine may be
prepared from 4-hydroxy-3-pyridine sulfonic acici by methods known in the art, including
methods disclosed in Canadian Patent No.: 1,051,888, and J. Med. Chem., 36, 3211-3213,
1993, the content of both are incorporated herein by reference.
By the methods of the present invention, a compound of formula IT, wherein X1 and
X2 are each independently chloro, fluoro or bromo; is added to a suitable organic solvent
(Scheme II). Preferably, X1 and X2 are chloro. Suitable organic solvents include acetonitrile,
ethers, such as, t-butyl methyl ether (MTBE), alcohols, such as, ethanol and isopropanol,
ketones, such as, methyl-isobutyl ketone (MDBK). ethyl methyl ketone and acetone; and
substituted or unsubstituted aromatics, such as, benzene and xylene. A preferred solvent is t-
butyl methyl ether. Ammonia is then added to the mixture which may cause the mixture to
rise in temperature. Preferably, about 2 mole equivalents of ammonia are added. Ammonia
may be added in the form of gaseous ammonia or ammonium hydroxide, and more
preferably as an aqueous solution of ammonium hydroxide. Preferably ammonium hydroxide
is added as a 25% aqueous solution. The solution is cooled to room temperature and stirred
until the reaction is substantially complete, e.g., 1 to 1.5 hours, preferably one hour.
Completion of the reaction may be monitored by pH; which is indicated when the pH stops
decreasing and stabilizes. The pH of the solution is adjusted to about 8 ± 0.1 by the addition
. of ammonium hydroxide to induce the precipitation of crystals of the compound of formula
III'. The compound of the formula III' wherein X1 is chloro, fluoro or bromo; is isolated
upon filtering the solution followed by drying (Scheme XT). Preferably X1 is chloro.
Scheme II


WO 01/70226 PCT/USO1/08866
In an embodiment of the present invention, a compound of the formula II, (3-
sulfonylchloride-4-chloro)pyridine, is added to an organic solvent. Suitable organic solvents
include acetonitrile, ethers, such as, t-butyl methyl ether (MTBE), alcohols, such as, ethanol
and isopropanol, ketones, such as, methyl-isobutyl ketone (MEBK), ethyl methyl ketone and
acetone; and substituted or unsubstituted aromatios, such as, benzene and xylene.A
preferred solvent is t-butyl methyl ether. Approximately 1.75 to about 2.25 mole equivalents
of ammonia is then added to the solution. Preferably, about 2.15 mole equivalents of
ammonia are added. Ammonia may be added in the form of gaseous ammonia or
ammonium hydroxide, and more preferably as an aqueous solution of ammonium hydroxide.
Preferably ammonium hydroxide is added as a 25% aqueous solution. Addition of the
ammonia may cause the temperature of the solution to rise. The solution is cooled to room
temperature and stirred until the reaction is substantially complete, e.g., 1 to 1.5 hours,
preferably one hour. Completion of the reaction nay be monitored by pH; which is
indicated when the pH stops decreasing and stabilizes. The pH of the solution is adjusted to
about 8 ± 1 by the addition of ammonium hydroxide to induce the precipitation of crystals of
(3-sulfonamide-4-chloro)pyridine, the compound of the formula HI. (3-Sulfonamide-4-
chloro)pyridine, the compound of the formula HI, is isolated upon filtering the solution
followed by drying. The (3-sulfonamide-4-chloro (pyridine is isolated in a high yield of
about 74 %. By the present methods, the (3-sulfomamide-4-chloro)pyridine is isolated in an
unexpectedly high purity of about 93% to about 97%.
Thus, surprisingly the present methods provide processes for making high purity (3-
sulfonamide-4-chloro)pyridine while using a high concentration of the starting material, (3-
sulfonylchloride-4-chloro)pyridine. In contrast to the known methods, the present methods
surprisingly yield (3-sulfonamide-4-chloro)pyridine substantially free of by-products
resulting from the condensation of the starting material and product, (3-sulfonylchloride-4-
chloro)pyridine and (3-sulfonamide-4-chloro)pyridine, which is observed in the known
processes.

WO 01/70226 PCT/US01/08866
Scheme III

The present method thus provides a new process with high yields and high purity which is suitable for use in large scale reactions. The high purity also reduces the need for additional purification steps. ,.
The present invention also relates to a new process for making torsemide from 3-sulfonamide-4-(3'-methylphenyl) aminopyridine. 3-SuIfomamide-4-(3'-methylphenyl) aminopyridine may be prepared from (3-sulfonamide-4-chloro)pyridine by methods known in the art, including methods disclosed in U.S. Patent No.: 3,904,636, the content of which is incorporated herein by reference.
By the processes of the present invention, a compound of the formula IV, 3-sulfomamide-4-(3'-methylphenyl) aminopyridine, is added to triethylamine (TEA) and an organic solvent (Scheme IV). Suitable solvents are acetonitrile, toluene, acetone, ethyl acetate and butyl acetate, and mixtures thereof. Preferred solvents are acetonitrile and acetone. A more preferred solvent is acetonitrile. Isopropyl isocyanate (IPIC) is then added dropwise to the solution and the solution is heated to about 40 'C. The resulting mixture is then stirred at about 38°C to about 42°C until there is complete dissolution of all the reactants, about 45 to 90 minutes. The mixture is then cooled to room temperature and stirred for a suitable time, about 1.5 to about 2.5 hours and preferably about 2 houis. The pH of the mixture is then adjusted to about 4.3±0.3, preferably to 4.3 with increasing the temperature to about 35°C. The pH may be lowered with hydrochloric acid. The mixture is cooled room temperature, followed by filtration and washing. The wet crude product is triturated, followed by drying to yield crude torsemide. The yield of isolated crude torsemide is about 81.5%. The purity of the isolated crude torsemide is about 98% to about: 99.9% which is a substantial improvement over the methods known in the art.

WO 01/70226 PCT/US01/08866
Scheme IV

EXAMPLES
The present invention will now be further explained in the following example. However, the present invention should not be construed as limited thereby. One of ordinary skill in the art will understand how to vary the exemplified preparations to obtain the desired results
Example 1 Synthesis of (3-sulfonamide-4-chloro)pyridine
In a 100 mL three necked flask equipped with magnetic stirrer, condenser, thermometer and dropping funnel (3-sulfonylchloride-4-chIoro)pyridine (10 g, 1 eq., 46.7 mmoles) was suspended in MTBE (30 mL) at room temperature. Ammonium hydroxide, 25% solution (13.5 mL, 2.13 eq.) was dropped into the suspension in a rate such that the temperature is allowed to increase to about 22 to abut 26 °C, this; temperature was maintained until all the ammonium hydroxide was added. The suspension was then to cooled to room temperature and was stirred for one hour. The pH of the suspension was adjusted to 8±0.1 by the addition of a few drops of ammonium hydroxide, 25% solution. The suspension was filtered and washed with water (2 x10 mL) and the wet product (~8 g) dried at 40°C, under the 1mm Hg vacuum. (3-Sulfonamide-4-chloro)pyridine was isolated in 74.4% yield, 6.7 g.
Exampi e 2 Synthesis of Torsemide
A 100 mL three necked flask, equipped with mechanical stirrer, thermometer and a


WO 01/70226 PCT7US01/08866 •
condenser was charged with acetonitrile (15 mL), 3-sulfomamide-4-(3'-methylphenyl)
aminopyridine (5 g), and triethyl amine (TEA) (5.3 mL). Isopropyl isocyanate (1.87 mL) was
added dropwise over 10 minutes and the whole mixture was stirred at 40 ± 2°C to complete
dissolution. The mixture was cooled to room temperature and stirred for another 2 hours. The
pH of the mixture was adjusted to 4.3 while increasing the temperature around 35 °C. The
mixture was cooled again to room temperature, filtered and washed with acetonitrile.water
(1:1) mixture (10 mL). The wet crude product was triturated in acetonitrile.water mixture
(5:1, 13 mL) at 60 °C for half an hour, filtered and washed with acetonitrile: water (5:1)
mixture (2 x 7 mL). The triturated product was then dried under high vacuum (3 mm Hg) at
50°C for 6 hours to get 5.4 g of crude torsemide (81.5% crude yield).
Although certain presently preferred embodiments of the invention have been described
herein, it will be apparent to those skilled in the art to which the invention pertains that
variations and modifications of the described embodiment may be made without departing
from the spirit and scope of the invention. Accordingly, it is intended that the invention be
limited only to the extent required by the appended claims and the applicable rules of law.


WE CLAIM:
1. A process for making (3-sulfonamide-4-chloro) pyridine, (3-sulfonamide-4-fluoro) pyridine or (3-sulfonamide-4-bromo) pyridine represented by the formula

comprising the steps of:
(a) adding of (3-sulfonylchloride-4-chloro) pyridine, (3-sulfonylchloride-4-
fluoro) pyridine, (3-sulfonylchloride-4-bromo)pyridine, (3-sulfonylfluoride-4-
chloro )pyridine 3-sulfonylfluoride-4-fluoro)pyridine, (3 -sulfonylfluoride-4-
bromo)pyridine, ( 3-sulfonylbromide-4-chloro)pyridine, (3 -sulfonylbrornide-
4-fluoro )pyridine or (3-sulfonylbromide-4-bromo pyridine represented by
the formula

to an organic solvent;
(b) adding ammonia; and
(c) isolating the (3-sulfonamide4-chloro)pyridine, (3-sulfonamide-4-fluoro)pyridine or (3-sulfonamide-4-bromo) pyridine of the formula
■//


wherein X1 and X2 are each independently chloro, fluoro or bromo.
2. The process as claimed in claim 1 wherein X1 and X2 are both chloro.
3. The process as claimed in claim 1 wherein the organic solvent is selected from the group consisting of t-butyl-methyl ether, toluene, acetonitrile, methyl-isobutyl ketone, ethyl-methyl ketone, acetone, benzene, xylene, ethanol and isopropanol.
4. The process as claimed in claim 3 wherein the organic solvent is t-butyl-methyl ether.
5. The process as claimed in claim 1 wherein the ammonia is an aqueous solution.
6. The process as claimed in claim 1 wherein the ammonia is added in an
amount of about 1.75 to about 2.25 mole equivalents.
Dated this 23rd day of September, 2002.
(RITUSHKA NEGI)
OF REMFRY & SAGAR
ATTORNEY FOR THE APPLICANTS

Documents

Application Documents

# Name Date
1 IN-PCT-2002-01320-MUM-ABSTRACT(AMENDED)-(5-1-2006).pdf 2018-08-08
1 in-pct-2002-01320-mum-form 5(23-09-2002).pdf 2002-09-23
2 IN-PCT-2002-01320-MUM-ASSIGNMENT(27-1-2003).pdf 2018-08-08
2 in-pct-2002-01320-mum-form 3(23-09-2002).pdf 2002-09-23
3 in-pct-2002-01320-mum-form 1a(23-09-2002).pdf 2002-09-23
3 IN-PCT-2002-01320-MUM-CANCELLED PAGES(12-1-2006).pdf 2018-08-08
4 in-pct-2002-01320-mum-form 18(22-02-2005).pdf 2005-02-22
4 IN-PCT-2002-01320-MUM-CLAIMS(AMENDED)-(12-1-2006).pdf 2018-08-08
5 in-pct-2002-01320-mum-form 4(13-10-2005).pdf 2005-10-13
5 in-pct-2002-01320-mum-claims(complete)-(23-9-2002).pdf 2018-08-08
6 in-pct-2002-01320-mum-power of attorney (05-01-2006).pdf 2006-01-05
6 IN-PCT-2002-01320-MUM-CORRESPONDENCE(12-1-2006).pdf 2018-08-08
7 in-pct-2002-01320-mum-petition under rule-138 (05-01-2006).pdf 2006-01-05
7 in-pct-2002-01320-mum-correspondence(28-3-2006).pdf 2018-08-08
8 in-pct-2002-01320-mum-petition under rule-137 (05-01-2006).pdf 2006-01-05
8 IN-PCT-2002-01320-MUM-CORRESPONDENCE(IPO)-(7-12-2008).pdf 2018-08-08
9 in-pct-2002-01320-mum-description(complete)-(23-9-2002).pdf 2018-08-08
9 in-pct-2002-01320-mum-form-pct-ipea-409 (05-01-2006).pdf 2006-01-05
10 in-pct-2002-01320-mum-form 2(complete)-(23-9-2002).pdf 2018-08-08
10 in-pct-2002-01320-mum-form 5(05-01-2006).pdf 2006-01-05
11 in-pct-2002-01320-mum-form 2(title page)-(complete)-(23-9-2002).pdf 2018-08-08
11 in-pct-2002-01320-mum-form 3(05-01-2006).pdf 2006-01-05
12 in-pct-2002-01320-mum-form 2(granted)-(05-01-2006).pdf 2006-01-05
12 IN-PCT-2002-01320-MUM-POWER OF AUTHORITY(27-1-2003).pdf 2018-08-08
13 IN-PCT-2002-01320-MUM-SPECIFICATION(AMENDED)-(5-1-2006).pdf 2018-08-08
14 in-pct-2002-01320-mum-form 1a(05-01-2006).pdf 2006-01-05
14 in-pct-2002-01320-mum-wo international publication report(23-9-2002).pdf 2018-08-08
15 IN-PCT-2002-01320-MUM-ABSTRACT(GRANTED)-(26-10-2006).pdf 2006-10-26
15 in-pct-2002-01320-mum-form 13(05-01-2006).pdf 2006-01-05
16 in-pct-2002-01320-mum-claims(granted)-(26-10-2006).pdf 2006-10-26
17 in-pct-2002-01320-mum-claim(granted)-(05-01-2006).pdf 2006-01-05
17 in-pct-2002-01320-mum-correspondence(ipo)-(26-10-2006).pdf 2006-10-26
18 in-pct-2002-01320-mum-form 2(granted)-(26-10-2006).pdf 2006-10-26
18 in-pct-2002-01320-mum-cancelled page (05-01-2006).pdf 2006-01-05
19 in-pct-2002-01320-mum-form 2(title page)-(granted)-(26-10-2006).pdf 2006-10-26
19 in-pct-2002-01320-mum-petition under rule-138 (13-01-2006).pdf 2006-01-13
20 in-pct-2002-01320-mum-correspondence (13-01-2006).pdf 2006-01-13
20 in-pct-2002-01320-mumdescription(granted)-(26-10-2006).pdf 2006-10-26
21 IN-PCT-2002-01320-MUM-CORRESPONDENCE(IPO)-(13-10-2006).pdf 2006-10-13
22 in-pct-2002-01320-mum-correspondence (13-01-2006).pdf 2006-01-13
22 in-pct-2002-01320-mumdescription(granted)-(26-10-2006).pdf 2006-10-26
23 in-pct-2002-01320-mum-form 2(title page)-(granted)-(26-10-2006).pdf 2006-10-26
23 in-pct-2002-01320-mum-petition under rule-138 (13-01-2006).pdf 2006-01-13
24 in-pct-2002-01320-mum-cancelled page (05-01-2006).pdf 2006-01-05
24 in-pct-2002-01320-mum-form 2(granted)-(26-10-2006).pdf 2006-10-26
25 in-pct-2002-01320-mum-correspondence(ipo)-(26-10-2006).pdf 2006-10-26
25 in-pct-2002-01320-mum-claim(granted)-(05-01-2006).pdf 2006-01-05
26 in-pct-2002-01320-mum-claims(granted)-(26-10-2006).pdf 2006-10-26
27 IN-PCT-2002-01320-MUM-ABSTRACT(GRANTED)-(26-10-2006).pdf 2006-10-26
27 in-pct-2002-01320-mum-form 13(05-01-2006).pdf 2006-01-05
28 in-pct-2002-01320-mum-form 1a(05-01-2006).pdf 2006-01-05
28 in-pct-2002-01320-mum-wo international publication report(23-9-2002).pdf 2018-08-08
29 IN-PCT-2002-01320-MUM-SPECIFICATION(AMENDED)-(5-1-2006).pdf 2018-08-08
30 in-pct-2002-01320-mum-form 2(granted)-(05-01-2006).pdf 2006-01-05
30 IN-PCT-2002-01320-MUM-POWER OF AUTHORITY(27-1-2003).pdf 2018-08-08
31 in-pct-2002-01320-mum-form 2(title page)-(complete)-(23-9-2002).pdf 2018-08-08
31 in-pct-2002-01320-mum-form 3(05-01-2006).pdf 2006-01-05
32 in-pct-2002-01320-mum-form 2(complete)-(23-9-2002).pdf 2018-08-08
32 in-pct-2002-01320-mum-form 5(05-01-2006).pdf 2006-01-05
33 in-pct-2002-01320-mum-form-pct-ipea-409 (05-01-2006).pdf 2006-01-05
33 in-pct-2002-01320-mum-description(complete)-(23-9-2002).pdf 2018-08-08
34 IN-PCT-2002-01320-MUM-CORRESPONDENCE(IPO)-(7-12-2008).pdf 2018-08-08
34 in-pct-2002-01320-mum-petition under rule-137 (05-01-2006).pdf 2006-01-05
35 in-pct-2002-01320-mum-correspondence(28-3-2006).pdf 2018-08-08
35 in-pct-2002-01320-mum-petition under rule-138 (05-01-2006).pdf 2006-01-05
36 IN-PCT-2002-01320-MUM-CORRESPONDENCE(12-1-2006).pdf 2018-08-08
36 in-pct-2002-01320-mum-power of attorney (05-01-2006).pdf 2006-01-05
37 in-pct-2002-01320-mum-claims(complete)-(23-9-2002).pdf 2018-08-08
37 in-pct-2002-01320-mum-form 4(13-10-2005).pdf 2005-10-13
38 IN-PCT-2002-01320-MUM-CLAIMS(AMENDED)-(12-1-2006).pdf 2018-08-08
38 in-pct-2002-01320-mum-form 18(22-02-2005).pdf 2005-02-22
39 in-pct-2002-01320-mum-form 1a(23-09-2002).pdf 2002-09-23
39 IN-PCT-2002-01320-MUM-CANCELLED PAGES(12-1-2006).pdf 2018-08-08
40 in-pct-2002-01320-mum-form 3(23-09-2002).pdf 2002-09-23
40 IN-PCT-2002-01320-MUM-ASSIGNMENT(27-1-2003).pdf 2018-08-08
41 in-pct-2002-01320-mum-form 5(23-09-2002).pdf 2002-09-23
41 IN-PCT-2002-01320-MUM-ABSTRACT(AMENDED)-(5-1-2006).pdf 2018-08-08

ERegister / Renewals